Assessment of the sensitivity of Eschericia coli to nitrofuran derivatives – an important issue in the context of growing antimicrobial resistance

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Urinary tract infections (UTIs) are among the most common infectious diseases. Antimicrobial therapy is the main component of UTI therapy. Current recommendations suggest the use of nitrofuran derivatives as first-line drugs for the treatment of uncomplicated UTIs. This group of drugs has the following advantages: slow development of resistance and high activity against E. coli. However, for some nitrofurans, it is impossible to obtain data on the prevalence of resistant strains due to the absence of sensitivity interpretation criteria. This review is devoted to the study of correlation of sensitivity data between class I nitrofuran derivatives and the possibility of comparing the activity of nitrofurantoin and furazidine against E.coli.

Full Text

Restricted Access

About the authors

Vladimir V. Rafalskiy

Immanuel Kant Baltic Federal University

Author for correspondence.
Email: v.rafalskiy@mail.ru
ORCID iD: 0000-0002-2503-9580

Ph.D., MD, professor, Head of the Department of General and Clinical Pharmacology; Director of the Clinical Trial Centre

Russian Federation, Kaliningrad

Alina A. Tsapkova

Immanuel Kant Baltic Federal University

Email: alina.tsapkova@mail.ru
ORCID iD: 0000-0002-2701-9719

Clinical pharmacologist, postgraduate student (3.3.6. pharmacology, clinical pharmacology)

Russian Federation, Kaliningrad

Larisa V. Mikhailova

Immanuel Kant Baltic Federal University

Email: mihalysa@mail.ru
ORCID iD: 0000-0001-5070-5955

Ph.D., associate Professor, Head of the Department of Therapy

Russian Federation, Kaliningrad

References

  1. Trześniewska-Ofiara Z., Mendrycka M., Cudo A., Szmulik M., Woźniak-Kosek A. Hospital urinary tract infections in healthcare units on the example of Mazovian specialist hospital ltd. Frontiers in cellular and infection microbiology. 2022;12:891796. doi: 10.3389/fcimb.2022.891796
  2. Kolman K.B. Cystitis and pyelonephritis: Diagnosis, Treatment, and Prevention. Primary Care: Clinics in Office Practice. 2019;46(2):191-202. doi: 10.1016/j.pop.2019.01.001
  3. Deltourbe L., Mariano L.L., Hreha T.N., Hunstad D.A., Ingersoll M.A. The impact of biological sex on diseases of the urinary tract. Mucosal immunology. 2022;15(5):857-66. doi: 10.1038/s41385-022-00549-0
  4. Laran O. Epidemiologic aspects of urinary tract infections. Proceedings of the international symposium «Urinary tract infections in outpatients» M. 1999:5-8. (Лоран О. Эпидемиологические аспекты инфекций мочевыводящих путей. Материалы международного симпозиума «Инфекции мочевыводящих путей у амбулаторных больных» М. 1999:5-8.)
  5. Rafalsky V., Khodnevich L. Prevalence and risk factors of uncomplicated UTI: multicentre study sonar. European Urology Supplements. 2008;7(3):267-. doi: 10.1016/S1569-9056(08)60781-2
  6. Rafalsky V.V., Moiseeva E.M. Epidemiology of uncomplicated outpatient urinary tract infections in the russian federation. Urology Herald. 2018;6(2):30-37. https://doi.org/10.21886/2308-6424-2018-6-2-30-37 (Рафальский В.В., Моисеева Е.М. Эпидемиология неосложненных внебольничных инфекций мочевыводящих путей в Российской Федерации. Вестник урологии. 2018(2):30-7. https://doi.org/10.21886/2308-6424-2018-6-2-30-37)
  7. Aliev Y., Arefieva O., Asfandiyarov F.R., Batiushin M.M., Bedzhanyan S., Belova A.N., et al. Infections and inflammation in urology. 2019. (Алиев Ю., Арефьева О., Асфандияров Ф.Р., Батюшин М.М., Беджанян С., Белова А.Н. и соавт. Инфекции и воспаления в урологии. 2019.)
  8. Meers P., Chow C. Bacteriostatic and bactericidal actions of boric acid against bacteria and fungi commonly found in urine. Journal of clinical pathology. 1990;43(6):484-7. doi: 10.1136/jcp.43.6.484
  9. Kozlov R., Palagin I., Ivanchik N., Trushin I., Dehnich A., Eidelstein M. et al. National monitoring of antibiotic resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter epidemiological study “DARMIS-2023”. Clinical Microbiology and Antimicrobial Chemotherapy. 2024;26(3):328-37. doi: 10.36488/cmac.2024.3.328-337 (Козлов Р., Палагин И., Иванчик Н., Трушин И., Дехнич А., Эйдельштейн М. и соавт. Национальный мониторинг антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового эпидемиологического исследования «ДАРМИС-2023». Клиническая микробиология и антимикробная химиотерапия. 2024;26(3):328-37. doi: 10.36488/cmac.2024.3.328-337)
  10. Tsapkova A.A., Mikhailova L.V., Korenev S.V., Kryukova N.O., Rafalskiy V.V. Real-world data for monitoring antimicrobial resistance to urinary tract infection pathogens. Real-World Data & Evidence. 2024;4(3):22-32. (In Russ.) https://doi.org/10.37489/2782-3784-myrwd-59. (Цапкова А.А., Михайлова Л.В., Коренев С.В., Крюкова Н.О., Рафальский В.В. Возможность использования данных реальной клинической практики для мониторинга за антимикробной резистентностью возбудителей инфекций мочевыводящих путей. Реальная клиническая практика: данные и доказательства. 2024;4(3):22-32. https://doi.org/10.37489/2782-3784-myrwd-59.)
  11. Yakovlev S., Suvorova M. Rationale for the choice of an antibiotic for urinary tract infections with an emphasis on the environmental safety of therapy. Urologiia. 2021(4):97-105. DOI: https://dx.doi.org/10.18565/urology.2021.4.97-105.
  12. Yakovlev S., Gadzhieva Z., Suvorova M. Antimicrobial activity of nitrofurans (nitrofurantoin, furazidine and furazidine potassium) against uropatogenic Escherichia coli isolated from patients with lower urinary tract infections. Urologiia. 2024(3):113-20. https://doi.org/10.18565/urology.2024.3.113-120.
  13. Rafalsky V. Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation. Urology Herald. 2018;6(3):50-6. https://doi.org/10.21886/2308-6424-2018-6-3-50-56
  14. Schito G.C., Naber K.G., Botto H., Palou J., Mazzei T., Gualco L., et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. International journal of antimicrobial agents. 2009;34(5):407-13.
  15. Palagin I., Sukhorukova M., Dehnich A., Eidelstein M., Shevelev A., Grinev A. et al. Current state of antibiotic resistance of pathogens of out- outpatient urinary tract infections in Russia: results of the DARMIS study (2010-2011). Clinical microbiology and antimicrobial chemotherapy. 2012;14(4):280-302. (Палагин И., Сухорукова М., Дехнич А., Эйдельштейн М., Шевелев А., Гринев А., и соавт. Современное состояние антибиотикорезистентности возбудителей внебольничных инфекций мочевых путей в России: результаты исследования «ДАРМИС»(2010–2011). Клиническая микробиология и антимикробная химиотерапия. 2012;14(4):280-302).
  16. Rafalskiy V., Pushkar D., Yakovlev S., Epstein O., Putilovskiy M., Tarasov S. et al. Distribution and antibiotic resistance profile of key Gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study. Journal of global antimicrobial resistance. 2020;21:188-94. doi: 10.1016/j.jgar.2019.09.008
  17. Palagin I., Sukhorukova M., Dehnich A., Eidelstein M., Perepanova T., Kozlov R. Antimicrobial resistance of pathogens causing community-acquired urinary tract infections in Russia: results of the multicenter study “DARMIS-2018”. Clinical microbiology and antimicrobial chemotherapy. 2019;21(2):134-46. doi: 10.36488/cmac.2019.2.134-146 (Палагин И., Сухорукова М., Дехнич А., Эйдельштейн М., Перепанова Т., Козлов Р. Антибиотикорезистентность возбудителей внебольничных инфекций мочевых путей в России: результаты многоцентрового исследования «ДАРМИС-2018». Клиническая микробиология и антимикробная химиотерапия. 2019;21(2):134-46. doi: 10.36488/cmac.2019.2.134-146)
  18. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0, 2025. Available from: https://www.eucast.org.
  19. Bonkat G., Bartoletti R., Bruyere F., Cai T., Geerlings S., Köves B. et al. EAU guidelines on urological infections. European association of urology. 2017;18:22-6.
  20. Hryniewicz W., Holecki M. Rekomendacje Diagnostyki. Terapii i Profilaktyki Zakazen Układu Moczowego u Dorosłych [Recommendations for Diagnostics, Therapy and Prevention of Urinary Tract Infections in Adults]. 2015.
  21. Kranz J., Schmidt S., Lebert C., Schneidewind L., Mandraka F., Kunze M. et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urologia internationalis. 2018;100(3):271-8. doi: 10.1159/000487645
  22. Практическое руководство по мониторингу антибиотикорезистентности с использованием платформы AMRcloud.: https://monitoring.amrcloud.net/docs/_print/.
  23. Paul H.E., Harrington C.M., Bender R.C., Briggs W.P. Resistance and cross resistance of bacteria to nitrofurans. Proceedings of the Society for Experimental Biology and Medicine. 1952;79(2):199-204.
  24. Klesiewicz K., Karczewska E., Nowak P., Mrowiec P., Skiba-Kurek I., Białecka J. et al. Comparative «in vitro» studies of furazidin and nitrofurantoin activities against common uropathogens including multidrug-resistant strains of «E. coli» and «S. aureus». 2018.
  25. Bielec F., Brauncajs M., Pastuszak-Lewandoska D. Nitrofuran derivatives cross-resistance evidence – uropathogenic Escherichia coli Nitrofurantoin and Furazidin in Vitro susceptibility testing. Journal of Clinical Medicine. 2023;12(16):5166. https://doi.org/10.3390/jcm12165166
  26. The data presented in the study – the susceptibility testing results for nitrofurantoin and furazidin using broth microdilution and disk diffusion methods. Available from: https://www.mdpi.com/article/10.3390/jcm12165166/s1.
  27. IHMA Europe Sàrl. Determination of Minimum Inhibitory Concentration (MIC) for furagin, furaginum solubile, ciprofloxacin, and nitrofurantoin against recent clinical isolates.- IHMA report study 3573.- Monthey, Switzerland, 2019. . Available from: https://www.ihma.com//.
  28. Sidorenko S.V., Ivanov D.V. Research Report «Study of sensitivity to Furamag of pathogens of outpatient urinary tract infections», GNCA: MCC1.040.156/1. . 2006. (Сидоренко С.В., Иванов Д.В. Отчет о НИР «Изучение чувствительности к фурамагу возбудителей внебольничных инфекций мочевыводящих путей», ГНЦА: MCC1.040.156/1. . 2006.)
  29. The list of interchangeable medicines from 08/02/2024 according to the website https://grls.rosminzdrav.ru / Access date 11/27/2024. (Перечень взаимозаменяемых лекарственных препаратов от 02.08.2024 по данным сайта https://grls.rosminzdrav.ru/ Дата доступа 27.11.2024).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Derivatives of nitrofurans of class I: nitrofurantoin (A), potassium furazidin (B), nifurtoinol (C).

Download (95KB)
Indexing metadata
3. Fig. 2. Distribution of MIC of nitrofurantoin and furazin for E. coli, adapted from [26]

Download (78KB)
Indexing metadata
4. Fig. 3. Distribution of MIC of nitrofurantoin and furazidin for E. coli, adapted from (27]

Download (65KB)
Indexing metadata
5. Fig. 4. Distribution of the MIC of furazidin potassium and nitrofurantoin for E. coli, n=552, adapted from [28]

Download (164KB)
Indexing metadata

Copyright (c) 2025 Bionika Media